RxDoctor Payments Data

Michael Kuhn, MD

Internal Medicine · Syracuse, NYNPI 1659726362

Payments from drug & device makers

$25,113in general payments, 2019–2025

Across 673 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vericel Corporation$14K
  • Pfizer$1K
  • AbbVie$1K
  • Viiv Healthcare Company$1K
  • Novo Nordisk$1K
  • GSK$1K
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$13,80655%
  • Food & beverage$11,12344%
  • Education$1851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,113 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$252,181
Medicare patients
509
Services billed
5,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$156,371
OzempicSemaglutide82$124,967
BiktarvyBictegrav/Emtricit/Tenofov Ala24$92,392
JardianceEmpagliflozin52$76,855
TrulicityDulaglutide44$64,278
Soliqua 100-33Insulin Glargine/Lixisenatide52$62,490
XareltoRivaroxaban31$41,259
DovatoDolutegravir Sodium/Lamivudine12$35,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$34,102
JanuviaSitagliptin Phosphate27$25,806
MyrbetriqMirabegron43$24,927
Breo ElliptaFluticasone/Vilanterol36$24,641
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$24,365
MounjaroTirzepatide22$23,932
EntrestoSacubitril/Valsartan30$20,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$1,248$160,402148 claims
Novo NordiskOzempic$1,087$124,96782 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta, Incruse Ellipta$1,050$107,157203 claims
GileadBiktarvy$888$92,39224 claims
Lilly USA, LLCTrulicity, Mounjaro$278$88,21066 claims
Boehringer IngelheimJardiance$169$76,85552 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$359$62,49052 claims
Johnson & JohnsonXarelto$497$41,25931 claims
Viiv Healthcare CompanyDovato$1,219$35,90712 claims
AstraZenecaBreztri Aerosphere, Symbicort$371$32,47541 claims
MerckJanuvia$201$25,80627 claims
Astellas Pharma US IncMyrbetriq$267$24,92743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →